ARTICLE | Distillery Therapeutics
Therapeutics: Integrin β1 (CD29); c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)
July 28, 2016 7:00 AM UTC
Cell culture and mouse studies suggest inhibiting CD29 could help treat c-MET-driven lung cancer. In a mouse c-MET-driven lung cancer cell line, siRNA targeting CD29 decreased invasiveness compared with scrambled siRNA. In a mouse model of c-MET-driven metastatic lung cancer, siRNA targeting CD29 decreased tumor growth and the number of tumors in the lungs compared with scrambled siRNA. Next steps include testing CD29 inhibitors in animal models of other c-MET-driven cancers. ...